Table 1.
Clinical and laboratory characteristics
| Characteristic | PUFA | Placebo |
|---|---|---|
|
| ||
| Number | 18 | 19 |
|
| ||
| Gender (M:F) | 6:12 | 2:17 |
|
| ||
| Age (y) | 51.5±6.9 | 49.8±12.1 |
|
| ||
| Ethnicity | ||
| Caucasian | 17 (94.4%) | 17 (89.5%) |
| Hispanic | 0 | 2 (10.5%) |
| Black | 1 (5.6%) | 0 |
|
| ||
| Hypertension | 17 (94.4%) | 13 (68.4%) |
|
| ||
| Hyperlipidemia | 9 (50%) | 11 (47.9%) |
|
| ||
| Laboratory results | ||
|
| ||
| AST (units/l) | 47.7±22.8 | 49.1±22.1 |
|
| ||
| ALT (units/l) | 60.1±27.6 | 66.0±43.7 |
|
| ||
| Total bilirubin (mg/dl) | 1.1±0.3 | 1.0±0.1 |
|
| ||
| Fasting glucose (mg/dl) | 129.9±36.5 | 120.5±37.6 |
|
| ||
| HOMA IR | 12.01±6.8 | 15.5±4.9 |
|
| ||
| HbA1C (g/dl) | 6.7±0.9 | 6.7±0.7 |
|
| ||
| Total cholesterol (mg/dl) | 177.9±40.2 | 189.6±47.4 |
|
| ||
| HDL (mg/dl) | 40.3±7.0 | 41.1±9.7 |
|
| ||
| Triglycerides (mg/dl) | 190.2±108.9 | 233.0±169.6 |
|
| ||
| Liver biopsy findings | ||
|
| ||
| Steatosis grade | ||
| 1 | 3 (16.7%) | 4 (21.1%) |
| 2 | 7 (38.9%) | 9 (47.4%) |
| 3 | 8 (44.4%) | 6 (31.6%) |
|
| ||
| Lobular inflammation grade | ||
| 1 | 2 (11.1%) | 4 (21.0%) |
| 2 | 12 (66.6%) | 9 (47.4%) |
| 3 | 4 (22.2%) | 6 (31.6%) |
|
| ||
| Ballooning grade | ||
| 1 | 6 (33.3%) | 7 (36.8%) |
| 2 | 12 (66.7%) | 12 (63.2%) |
|
| ||
| Fibrosis grade | ||
| 1 | 6 (33.3%) | 7 (36.8%) |
| 2 | 6 (33.3%) | 7 (36.8%) |
| 3 | 6 (33.3%) | 5 (26.3%) |
All values mean±SD